Asset Prioritization Analysis to provide Strategic direction to the client in Atrial Fibrillation space along with Identification of best possible asset to support client’s future development and licensing needs.
A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.
Develop R&D strategy with reliable analysis of your asset group and come up focused list of prioritized assets.
Achieve Breakthroughs with all-encompassing Market Outlook Research